Neoadjuvant chemotherapy (NACT) is the standard treatment for patients with HER2 positive BC, triple-negative BC, and patients presenting with an inoperable primary tumor (16); this has enabled conversion from mastectomy to less extensive partial mastectomy (17). This evidence concerns the gene ERBB2 and breast cancer.